Cataplexy clinical trials at UCSF
1 research study open to eligible people
Showing trials for
HBS-301 in Participants With Narcolepsy
open to eligible people ages 18 years and up
This is a Phase 3, multicenter, randomized, double-blind, parallel-group, placebo-controlled clinical study to assess the efficacy and safety of HBS-301 in treating excessive daytime sleepiness (EDS), cataplexy, sleepiness/wakefulness, and fatigue in adult participants (ages ≥18 years) with narcolepsy.
San Francisco, California and other locations
Our lead scientists for Cataplexy research studies include Andrew Krystal, MD.
Last updated: